Group 1 - The Hong Kong stock market saw a rebound on January 13, with the healthcare sector, particularly innovative drugs and medical devices, experiencing significant growth. The Hong Kong Medical ETF (159506) rose by 3.44%, with notable increases in component stocks such as Medical Mind (over 12%), Sangfor Technologies, and WuXi Biologics (over 6%) [1] - WuXi AppTec, a leading innovative drug company, announced a performance forecast for 2025, projecting a revenue increase of 15.84% year-on-year and a net profit attributable to shareholders growth of 41.33%, exceeding market expectations and boosting investor sentiment [1] - The collaboration between Rongchang Biologics and AbbVie on a core dual-antibody product includes an upfront payment of $650 million and potential milestone payments totaling up to $4.95 billion, indicating strong market interest and unexpected developments in business deals [1] Group 2 - Haitong Securities noted that multinational corporations (MNCs) have not altered their strategy for expansion in China, with 49 business development (BD) transactions occurring since October of the previous year, totaling over $39 billion. Although some anticipated BD transactions have faced delays, the trend of innovative drugs going overseas remains strong [1] - The Hong Kong Medical ETF (159506) closely tracks the Hang Seng Hong Kong Stock Connect Healthcare Index (HSSCHI), which excludes companies with the lowest average R&D to revenue ratios over the past two years. This focus on R&D spending and innovative drug business helps investors accurately capture investment opportunities in the Hong Kong healthcare sector [2]

Group 1 - The core viewpoint of the news highlights a strong recovery in the innovative drug sector, with significant stock price increases and positive market sentiment returning to the pharmaceutical industry [1][2] - The Hong Kong pharmaceutical ETF (159718.SZ) has risen by 2.77%, marking a seven-day consecutive increase, driven by strong performances from constituent stocks such as Rongchang Biologics, which rose by 10.56%, and WuXi AppTec, which increased by 7.40% [1] - Rongchang Biologics has entered a substantial licensing agreement with AbbVie for a core dual-antibody product, with an upfront payment of $650 million and potential milestone payments totaling up to $4.95 billion, exceeding expectations [1] Group 2 - WuXi AppTec has announced a revenue forecast for 2025 of 45.456 billion yuan, representing a year-on-year growth of 15.84%, and an adjusted net profit of 14.957 billion yuan, reflecting a 41.33% increase, indicating accelerated performance [1] - Recent market trends show a recovery in the pharmaceutical sector, with emerging hotspots in brain-computer interfaces, small nucleic acid drugs, and AI healthcare, suggesting promising investment opportunities in the industry [1][2] - The innovative drug sector is expected to remain the most important investment theme in the pharmaceutical industry through 2026, with improving market conditions and catalysts expected to drive stock prices [2]